Form D · Biotechnology
Terremoto Biosciences, Inc.
South San Francisco, CA · CIK 0002130748
Offering snapshot reported Apr 22, 2026 · SEC filing
- Reported sold
- $40.7M Offering amount: $109M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 10, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 22, 2026 | Initial | $40,725,000 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-581389
Source: Form D, filed Apr 22, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Charles Baum | Director, Executive |
| James Christensen | Director, Executive |
| Michael Goller | Director |
| Reid Huber | Director |
| Grace Lu | Executive |
| Daniel O'connell | Director |
| Peter Thompson | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
230 East Grand Avenue, Suite 200
South San Francisco, CA, 94080
South San Francisco, CA, 94080